论文部分内容阅读
目的探讨用尿激酶治疗急性心肌梗死(AMI)的临床疗效。方法对2009年1月—2011年1月期间我院收治的89例ST段抬高型急性心肌梗死患者的诊治资料进行分析研究。这89例患者在进行常规吸氧、心电监护、镇静等治疗及卧床休息的基础上,接受我们实施的尿激酶溶栓治疗。结果在这89例患者中,溶栓治疗成功者有76例,占总数的85%。结论尿激酶具有良好的溶栓作用,用此药治疗急性心肌梗死可提高患者闭塞血管再通的几率,而且方法简单,适合在基层医院推广使用。
Objective To investigate the clinical efficacy of urokinase in the treatment of acute myocardial infarction (AMI). Methods From January 2009 to January 2011 in our hospital during the treatment of 89 cases of ST-segment elevation acute myocardial infarction in patients with diagnosis and treatment data were analyzed. The 89 patients underwent routine thrombolysis with urokinase on the basis of conventional oxygen inhalation, ECG monitoring, sedation and bed rest. Results Of the 89 patients, 76 were successful thrombolytic therapy, accounting for 85% of the total. Conclusion Urokinase has a good thrombolytic effect, the use of this drug in patients with acute myocardial infarction can improve the probability of occlusion of patients with recanalization, and the method is simple, suitable for promotion and use in primary hospitals.